CC
GTHX

Centiva Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Centiva Capital’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,737
Closed -$58K – 1892
2022
Q2 		$58K Buy
+11,737
New +$65K ﹤0.01% 1466

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Centiva Capital's GTHX Position: Q3 2022 in Review

Centiva Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2022, closing a stake of 11,737 shares — an estimated $58K sold.

Centiva Capital first reported a position in GTHX in Q2 2022 and held it in 1 quarter. The position peaked at $58K in Q2 2022. 104 funds tracked by Wall St. Rank hold GTHX as of Q3 2022.

  • Centiva Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Centiva Capital sold 11,737 G1 Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $58K.
  • Centiva Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Centiva Capital's G1 Therapeutics, Inc. Common Stock position peaked at $58K in Q2 2022.
  • 104 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Centiva Capital's 13F filing for Q3 2022, filed 14 Nov 2022.